RPC01-3204
Showing 1 - 25 of 152
Prostate Cancer Trial in Worldwide (Relugolix, Leuprolide Acetate)
Rheumatoid Arthritis Trial in Worldwide (Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate)
Completed
- Rheumatoid Arthritis
- Placebo to Upadacitinib
- +3 more
-
La Mesa, California
- +289 more
Dec 1, 2022
Psoriatic Arthritis Trial in Worldwide (Apremilast 20mg, Apremilast 30mg, Placebo)
Completed
- Psoriatic Arthritis
- Apremilast 20mg
- +2 more
-
Phoenix, Arizona
- +117 more
May 26, 2022
Coronary Artery Disease (CAD) Trial in Worldwide (Ticagrelor, Acetylsalicylic Acid, Clopidogrel)
Completed
- Coronary Artery Disease (CAD)
- Ticagrelor
- +2 more
-
Brisbane, Australia
- +129 more
Mar 13, 2022
Clear Cell Renal Cell Carcinoma Trial in Worldwide (Nivolumab and rHuPH20, Nivolumab)
Recruiting
- Clear Cell Renal Cell Carcinoma
- Nivolumab and rHuPH20
- Nivolumab
-
Chicago, Illinois
- +104 more
Jan 13, 2023
Glaucoma, Acupuncture, Intraocular Pressure Trial in Taichung (Acupuncture, Acupuncture )
Not yet recruiting
- Glaucoma
- +2 more
- Acupuncture
- Acupuncture placebo
-
Taichung, TaiwanChina Medical University Hospital
Mar 1, 2023
Atopic Dermatitis Trial in Worldwide (Upadacitinib)
Not yet recruiting
- Atopic Dermatitis
-
Kogarah, New South Wales, Australia
- +136 more
Aug 18, 2022
Chronic Myeloproliferative Disorders, GVHD, Leukemia Trial in Buffalo (sargramostim)
Completed
- Chronic Myeloproliferative Disorders
- +5 more
- sargramostim
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 3, 2022
Diabetic Kidney Disease Trial in Worldwide (Finerenone (BAY94-8862), Placebo)
Completed
- Diabetic Kidney Disease
- Finerenone (BAY94-8862)
- Placebo
-
Birmingham, Alabama
- +974 more
Apr 13, 2022
Rheumatoid Arthritis Trial in Worldwide (Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib)
Active, not recruiting
- Rheumatoid Arthritis
- Placebo for Adalimumab
- +3 more
-
Birmingham, Alabama
- +369 more
Jun 14, 2022
Atopic Dermatitis Trial in Worldwide (Placebo, Upadacitinib, Topical corticosteroids (TCS))
Active, not recruiting
- Atopic Dermatitis
- Placebo
- +2 more
-
Birmingham, Alabama
- +189 more
Mar 8, 2022
Moderate-to-Severe Atopic Dermatitis Trial in Worldwide (Placebo, Nemolizumab)
Active, not recruiting
- Moderate-to-Severe Atopic Dermatitis
- Placebo
- Nemolizumab
-
Little Rock, Arkansas
- +201 more
Aug 24, 2022
COPD Trial in Worldwide (Benralizumab, Placebo)
Recruiting
- Chronic Obstructive Pulmonary Disease
- Benralizumab
- Placebo
-
Montgomery, Alabama
- +400 more
Jan 11, 2023
Chronic Kidney Disease Trial in Worldwide (Finerenone (BAY94-8862), Placebo)
Completed
- Chronic Kidney Disease
- Finerenone (BAY94-8862)
- Placebo
-
Birmingham, Alabama
- +977 more
Jun 29, 2021
Respiratory Syncytial Virus Infection Trial in Worldwide (MK-1654, Placebo)
Recruiting
- Respiratory Syncytial Virus Infection
- MK-1654
- Placebo
-
Dothan, Alabama
- +149 more
Mar 31, 2022
Atopic Dermatitis Trial in Australia, New Zealand, United States (BTX 1204, Vehicle)
Ulcerative Colitis Trial in Worldwide (Placebo, PF-00547659 SC Injection)
Completed
- Ulcerative Colitis
- Placebo
- PF-00547659 SC Injection
-
Scottsdale, Arizona
- +189 more
Jun 2, 2021
Traumatic Hemothorax Trial in Medellin (Pleural aspiration)
Recruiting
- Traumatic Hemothorax
- Pleural aspiration
-
Medellin, Antioquia, ColombiaPablo Tobon Uribe Hospital
Apr 6, 2022
Trauma, Traumatic Injury, Traumatic Brain Injury Trial in Worldwide (Epoetin Alfa 40000 UNT/ML, Sodium Chloride 0.9%)
Recruiting
- Trauma
- +7 more
- Epoetin Alfa 40000 UNT/ML
- Sodium Chloride 0.9%
-
Camperdown, New South Wales, Australia
- +34 more
Nov 9, 2022
Ulcerative Colitis Trial in Worldwide (Placebo, Guselkumab)
Active, not recruiting
- Ulcerative Colitis
- Placebo
- Guselkumab
-
Lancaster, California
- +390 more
Jan 17, 2023